208 related articles for article (PubMed ID: 12740756)
1. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
[TBL] [Abstract][Full Text] [Related]
2. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
Normann C; Schmauss M; Bakri N; Gerwe M; Schreiner A
Pharmacopsychiatry; 2006 Nov; 39(6):209-12. PubMed ID: 17124642
[TBL] [Abstract][Full Text] [Related]
3. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
4. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.
Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
J Clin Psychopharmacol; 2005 Aug; 25(4):293-300. PubMed ID: 16012270
[TBL] [Abstract][Full Text] [Related]
5. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.
Hovens JE; Dries PJ; Melman CT; Wapenaar RJ; Loonen AJ
J Psychopharmacol; 2005 Jan; 19(1):51-7. PubMed ID: 15671129
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
7. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
8. [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone].
Sannomiya M; Katsu H; Nakayama K
Seishin Shinkeigaku Zasshi; 2003; 105(5):643-58. PubMed ID: 12875232
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Yoshimura R; Shinkai K; Ueda N; Nakamura J
Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
[TBL] [Abstract][Full Text] [Related]
10. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
Citrome L; Shope CB; Nolan KA; Czobor P; Volavka J
Int Clin Psychopharmacol; 2007 Nov; 22(6):356-62. PubMed ID: 17917554
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
13. Acute and continuation risperidone monotherapy in mania.
Vieta E; Brugué E; Goikolea JM; Sánchez-Moreno J; Reinares M; Comes M; Colom F; Martínez-Arán A; Benabarre A; Torrent C
Hum Psychopharmacol; 2004 Jan; 19(1):41-5. PubMed ID: 14716711
[TBL] [Abstract][Full Text] [Related]
14. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
15. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
Yasui-Furukori N; Saito M; Nakagami T; Furukori H; Suzuki A; Kondo T; Kaneko S
J Psychopharmacol; 2010 Jul; 24(7):987-94. PubMed ID: 19477882
[TBL] [Abstract][Full Text] [Related]
16. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
17. [Risperidone in the treatment of acute exacerbation of schizophrenia symptoms].
Gutiérrez M; Gibert J; Bobes J; Herráiz ML; Fernández A
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(2):83-9. PubMed ID: 9595821
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
Himei A; Okamura T
Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
[TBL] [Abstract][Full Text] [Related]
19. Testosterone in first-episode schizophrenia.
Cesková E; Prikryl R; Kaspárek T
Neuro Endocrinol Lett; 2007 Dec; 28(6):811-4. PubMed ID: 18063925
[TBL] [Abstract][Full Text] [Related]
20. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
